Changes in LV mass, and systolic and diastolic function in the study groups
| Placebo group | Metoprolol group | p Value | |||
|---|---|---|---|---|---|
| Before | After | Before | After | ||
| LVEF (%) | 37.89±5.08 | 35.84±5.26* | 38.65±5.27 | 42.84±4.92** | <0.001 |
| LV mass (g) | 174.32±60.16 | 200.15±86.8* | 154.31±41.29 | 144.26±39.6 | <0.001 |
| ESV (cm3) | 47.37±27.31 | 57.42±55.29 | 42.19±9.14 | 36.73±7.11** | <0.001 |
| ESD (mm) | 31.53±9.29 | 30.47±8.70 | 28.88±4.09 | 29.88±4.91 | 0.267 |
| EDD (mm) | 44.95±9.08 | 48.57±8.98* | 42.85±6.11 | 44.03±6.19 | 0.268 |
| S velocity (m/s) | 0.150±0.035 | 0.138±0.038 | 0.138±0.037 | 0.142±0.038 | 0.067 |
| Tei index | 0.53±0.161 | 0.59±0.108 | 0.607±0.181 | 0.615±0.187 | 0.206 |
| PCWP (mm Hg) | 6.43±1.72 | 6.97±1.78 | 7.04±2.56 | 7.25±3.93 | 0.535 |
| E velocity (m/s) | 0.23±0.039 | 0.22±0.046 | 0.22±0.051 | 0.23±0.061 | 0.506 |
| LA size (mm) | 32.53±7.0 | 35.84±9.2 | 30.04±4.4 | 31.34±3.8 | 0.519 |
*p<0.05; **p<0.01.
EDD, end diastolic dimension; ESD, end systolic dimension; ESV, end systolic volume; LA, left atrium; LVEF, left ventricular ejection fraction; LV, left ventricle; PCWP, pulmonary capillary wedge pressure; S velocity, peak systolic velocity.